Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine

• Main Authors: Cristina Lucía Dávila-Fajardo, Xando Díaz-Villamarín, Alba Antúnez-Rodríguez, Ana Estefanía Fernández-Gómez, Paloma García-Navas, Luis Javier Martínez-González, José Augusto Dávila-Fajardo, José Cabeza Barrera
• Format: Article
• Language: English
• Published: MDPI AG 2019-04-01
• Series: Genes
• Subjects: pharmacogenetics; clopidogrel; warfarin; acenocoumarol
• Online Access: https://www.mdpi.com/2073-4425/10/4/261

There is a special interest in the implementation of pharmacogenetics in clinical practice, although there are some barriers that are preventing this integration. A large part of these pharmacogenetic tests are focused on drugs used in oncology and psychiatry fields and for antiviral drugs. However, the scientific evidence is also high for other drugs used in other medical areas, for example, in cardiology. In this article, we discuss the evidence and guidelines currently available on pharmacogenetics for clopidogrel, warfarin, acenocoumarol, and simvastatin and its implementation in daily clinical practice.